Summary: Life-saving protein-based therapeutics are becoming an increasingly important therapeutic option. Analytical methods are deployed from the earliest moments of discovery up through delivery of approved protein therapeutics to patients, ensuring a safe and effective supply of drugs. So what is the role of analytical chemistry in the evaluation of protein drugs? When are certain approaches first engaged and what are the tools needed and methodologies employed? We’ll look at some of the key analysis techniques for proteins.
Presenter: Mike Molloy, Technical director of the Biologics Laboratory
Mike Molloy has been with Boston Analytical since 2012, serving first as the Director of the QC Chemistry laboratory, then heading Analytical Development in Chemistry and most recently serving as the Technical director overseeing the Biologics Laboratory. Prior to joining Boston Analytical, he spent twenty years in pharmaceutical development at Biogen, developing bioassays for product characterization and methods for bioanalysis of clinical trial pharmacokinetics samples. Molloy was head of laboratory operations in the Preclinical and Clinical Developments Sciences group at Biogen. Mike holds a master’s degree in biology from Umass Lowell and a bachelor’s in biology from UNH.